5 Stocks Advancing The Drugs Industry

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 60 points (0.4%) at 15,029 as of Tuesday, May 7, 2013, 12:54 PM ET. The NYSE advances/declines ratio sits at 1,907 issues advancing vs. 994 declining with 159 unchanged.

The Drugs industry currently sits down 0.07 versus the S&P 500, which is up 0.3%. Top gainers within the industry include Sanofi ( SNY), up 1.0%, and Amgen ( AMGN), up 0.6%. On the negative front, top decliners within the industry include Biogen Idec ( BIIB), down 0.62, and AstraZeneca ( AZN), down 0.46.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Drugs industry higher today. As of noon trading, Teva Pharmaceutical Industries is up $0.46 (1.20) to $38.77 on light volume Thus far, 1.6 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $38.32-$38.77 after having opened the day at $38.54 as compared to the previous trading day's close of $38.31.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.0 billion and is part of the health care sector. The company has a P/E ratio of 17.1, below the S&P 500 P/E ratio of 17.7. Shares are up 2.6% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 15 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Teva Pharmaceutical Industries Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon